Results 251 to 260 of about 12,230 (281)

Cytoprotective effects of trimetazidine in carmustine cholestasis

Experimental and Toxicologic Pathology, 1999
Carmustine [1 ,3-bis(2-chloroethyl)-1-nitrosurea (BCNU)] is an antitumour agent, however, its usefulness has been limited by a side effect; which involves pericholangitis and intrahepatic cholestasis. The primary effects of cholestasis is well known; bile flow retention, intracellular Ca++ accumulation and acidosis although it may lead to ...
Girgin, F, Tuzun, S, Demir, A, Kuralay, F, Ozutemiz, O, Tanyalcin, T   +5 more
openaire   +4 more sources

Cardioprotective effects of trimetazidine: a review

Current Medical Research and Opinion, 2003
The efficacy of trimetazidine, an anti-ischaemic agent, has been largely assessed and presented in the international literature through its metabolic effects, selective and specific fatty acid oxidation inhibition and lack of haemodynamic effects in stable angina pectoris. As such, trimetazidine has opened up a new class of metabolic agents that reduce
openaire   +3 more sources

Trimetazidine alleviates paclitaxel-induced peripheral neuropathy through modulation of TLR4/p38/NFκB and klotho protein expression.

Chemico-Biological Interactions, 2023
A. Hammad, M. Sayed-Ahmed, S. M. A. Abdel Hafez, Ahmed R. N. Ibrahim, M. Khalifa, M. El-Daly   +5 more
semanticscholar   +1 more source

Evaluating the protective role of trimetazidine versus nano-trimetazidine in amelioration of bilateral renal ischemia/reperfusion induced neuro-degeneration: Implications of ERK1/2, JNK and Galectin-3 /NF-κB/TNF-α/HMGB-1 signaling.

Tissue & Cell, 2023
Fatma E. Hassan, B. Aboulhoda, Isra H. Ali, Heba M. Elwi, L. Matter, H. Abdallah, Mohamed Mansour Khalifa, Asmaa Selmy, Mansour A. Alghamdi, S. Morsy, Basant A Al Dreny   +10 more
semanticscholar   +1 more source

Antioxidant Properties of an Antiischaemic Agent : Trimetazidine

1990
Trimetazidine (TMZ) has now been widely used throughout the world for more than ten years for the treatment of cellular manifestation of ischaemic disorders including coronary heart diseases, retinopathies and cochleo-vestibular diseases. Its efficacy has been assessed in double-blind studies versus placebo and versus reference drugs.
P, Clauser, C, Harpey
openaire   +2 more sources

Trimetazidine affects pyroptosis by targeting GSDMD in myocardial ischemia/reperfusion injury

Inflammation Research, 2022
Xudong Chen, Shuang Lin, S. Dai, Jibo Han, P. Shan, Weiqi Wang, Zhouqing Huang, Bozhi Ye, Weijian Huang   +8 more
semanticscholar   +1 more source

Trimetazidine

Reactions Weekly, 2021
openaire   +1 more source

WITHDRAWN: Trimetazidine for stable angina.

The Cochrane database of systematic reviews, 2017
Patients with stable angina not controlled by monotherapy with nitrates, beta blockers, or calcium channel blockers are often treated with combinations of these drugs. There may be adverse effects from, or contraindications to, the use of combinations.
Agustín, Ciapponi, Rudolf, Pizarro, Jeff, Harrison   +2 more
openaire   +1 more source

Trimetazidine attenuates cyclophosphamide-induced cystitis by inhibiting TLR4-mediated NFκB signaling in mice.

Life Science, 2022
Seçkin Engin, Elif Nur Barut, Yeşim Kaya Yaşar, A. Soysal, Tuğba Arıcı, G. Kerimoğlu, M. Kadioglu, S. Sezen   +7 more
semanticscholar   +1 more source

Trimetazidine

Reactions Weekly, 2008
openaire   +1 more source